DelveInsight has launched a new report on Cholestatic Pruritus Pipeline
Cholestasis is defined as a decrease in bile flow due to the impaired secretion by hepatocytes or due to the obstruction of bile flow through intra-or extra-hepatic bile ducts. This impairment in bile secretion occurs at somewhere between the liver cells (which produce bile) and the duodenum (the first segment of the small intestine).
Browse Free Sample copy- https://www.delveinsight.com/sample-request/cholestatic-pruritus-pipeline-insight
Cholestatic Pruritus Pipeline analysis across different stages of development (Phase I, II, and III), different emerging trends and comparative analysis of Cholestatic Pruritus Pipeline products with detailed clinical profiles, key competitors, launch date along with product development activities.
Cholestatic Pruritus Pipeline
The dynamics of Cholestatic Pruritus market is anticipated to change in the coming years owing to the improvement in the diagnostic methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and also expects the launch of emerging therapies during the forecast period of 2020–2030. Major Pharma giants are thoroughly working toward the development of new treatment therapies for this indication, in order to provide better relief for the symptoms and hence improve the QoL of patients with Cholestasis.
Cholestatic Pruritus Symptoms
Pruritus is a distressing manifestation of both intrahepatic cholestasis and extrahepatic biliary obstruction. Intrahepatic cholestasis processes associated with pruritus include Primary Biliary Cirrhosis (PBC), and cholestasis of pregnancy (pruritus gravidarum), drug-induced cholestasis, and viral hepatitis. However, pruritus is also seen in extrahepatic cholestatic liver diseases such as primary sclerosing cholangitis (PSC), and cancer of the head of the pancreas. Historically, pruritus has been observed to accompany jaundice, but it is not uncommon to see pruritus as the first manifestation of cholestasis even before the onset of jaundice or other symptoms. There is considerable variation in the frequency and prevalence of pruritus in different cholestatic conditions.
Emerging therapies included in the report
Cholestatic Pruritus Treatment
Efficient drug discovery has been hindered by a lack of robust knowledge of the molecular mechanisms of Cholestatic Pruritus. However, recent evidence on autotaxin, lysophosphatidic acid (LPA), and advances in bile acid physiology have initiated the development of novel agents that might represent an alternative to currently ongoing research on the so far enigmatic pathophysiology of cholestatic itch may provide us with new therapeutic targets in the near future current treatments. Experimental evidence has shown that autotaxin and LPA are markedly elevated in the serum of patients with Cholestatic Pruritus and that their levels closely correlate with itch intensity.
Cholestatic Pruritus Report Scope
Table of content
1. Report Introduction
2. Cholestatic Pruritus
3. Cholestatic Pruritus Current Treatment Patterns
4. Cholestatic Pruritus – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Cholestatic Pruritus Late Stage Products (Phase-III)
7. Cholestatic Pruritus Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Cholestatic Pruritus Discontinued Products
13. Cholestatic Pruritus Product Profiles
14. Cholestatic Pruritus Key Companies
15. Cholestatic Pruritus Key Products
16. Dormant and Discontinued Products
17. Cholestatic Pruritus Unmet Needs
18. Cholestatic Pruritus Future Perspectives
19. Cholestatic Pruritus Analyst Review
20. Appendix
21. Report Methodology
What are the report highlights?
Related Reports
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/